|
Symptoms—n (%)
| |
|
Fatigue
|
25 (86%)
|
|
Muscle pain
|
18 (62%)
|
|
Dyspnea
|
14 (48%)
|
|
Inappropriate sinus tachycardia
|
9 (31%)
|
|
Low-grade fever
|
9 (31%)
|
|
Functional status
| |
|
Grade 0
|
0 (0%)
|
|
Grade I—n (%)
|
7 (24%)
|
|
Grade II—n (%)
|
8 (27.5%)
|
|
Grade III—n (%)
|
5 (17.2%)
|
|
Grade IV—n (%)
|
9 (31%)
|
|
Median number of days until evaluation days (IQR)
|
57 (42–71)
|
|
Median number of days to extra-respiratory positive RT- PCR (IQR)
|
55 (39–67)
|
|
SARS-CoV-2 IgG tests—n (%)
|
25 (86%)
|
|
Hemoglobin (g/dL)—median (IQR)
|
14.3 (13.2–15)
|
|
Lymphocyte count (× 10E3/µl)—median (IQR)
|
1.4 (1.2–1.7)
|
|
Platelet count (× 10E3/µL)—median (IQR)
|
202 (184–238)
|
|
Serum creatinine (mg/dL)—median (IQR)
|
0.72 (0.63–0.82)
|
|
Alanin aminotransferase (U/L)—median (IQR)
|
24 (20–39.5)
|
|
> 40 U/L—n (%)
|
7 (25%)
|
|
≤ 40 U/L—n (%)
|
21 (75%)
|
|
Ferritin (µg/L)—median (IQR)
|
100 (38.5–204)
|
|
> 205 (µg/L)—n (%)
|
7 (25%)
|
|
≤ 205 (µg/L)—n (%)
|
21 (75%)
|
|
Positive SARS-CoV-2 RT-PCR
| |
|
Plasma—n (%)
|
13 (44.8%)
|
|
Stool—n (%)
|
5 (17.2%)
|
|
Urine—n (%)
|
4 (13.7%)
|
|
At least one positive result—n (%)
|
15 (51.7%)
|
|
Two positive results—n (%)
|
5 (17,2%)
|
|
Three positive results—n (%)
|
2 (6.8%)
|
